{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-013017","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.867088+00:00","generated_at":"2026-06-25T18:45:29.739234+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Co-Diagnostics reports Q1 revenue $22.7M, net income $11.7M ($0.34 EPS); no guidance given","bullets":["Q1 revenue $22.7M, record first quarter; net income $11.7M ($0.34 diluted EPS) vs $7.9M a year ago.","Gross profit $19.4M (85.5% margin); operating income $9.8M down from $10.3M on higher R&D.","Cash, equivalents, and marketable securities $97.4M, up $7.5M from Dec 2021.","Co-Dx PCR home testing platform progressing toward FDA submission later this year.","No quarterly guidance provided due to diminished COVID-19 test sales forecasting ability."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-013017","json":"https://secwatch.observer/filing/0001493152-22-013017.json","markdown":"https://secwatch.observer/filing/0001493152-22-013017.md","text":"https://secwatch.observer/filing/0001493152-22-013017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315222013017/0001493152-22-013017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315222013017/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:45:29.739234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}